Oct 1, 2026 8:00 am EDT Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Sep 23, 2026 4:05 pm EDT Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
Sep 8, 2026 5:43 pm EDT Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Aug 6, 2026 4:05 pm EDT Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Jul 30, 2026 8:00 am EDT Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Jun 29, 2026 8:30 am EDT Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
May 7, 2026 4:05 pm EDT Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Apr 6, 2026 9:00 am EDT Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Mar 5, 2026 4:01 pm EST Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
